If your email program has trouble displaying this email, view as a webpage. FY 2023 PDUFA Dear Colleague Letter In preparation for FDA's FY 2023 PDUFA program fee invoices, the Dear Colleague Letter (DCL) was emailed on Monday, May 2, 2022 for PDUFA user fee eligible products.  Please submit your response to CDERCollections@fda.hhs.gov by Wednesday, June 1, 2022.  If you have any questions regarding the DCL, please send an email to the Dear Colleague Letter Coordinator at CDERCollections@fda.hhs.gov.  The DCL is available at: https://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm149212.htm.  The DCL is also available on the PDUFA website, under "Related Info" then "PDUFA Letters."    ** Please note: This update is only applicable to companies that have PDUFA user fee eligible products for Prescription drug program fees.**   Learn More

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA